PFBT
BTAI

Parkside Financial Bank & Trust’s BioXcel Therapeutics BTAI Stock Holding History

Parkside Financial Bank & Trust’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158 Hold
112
– – ﹤0.01% 2675
2026
Q1 		$151 Hold
112
– – ﹤0.01% 2653
2025
Q4 		$180 Hold
112
– – ﹤0.01% 2641
2025
Q3 		$287 Hold
112
– – ﹤0.01% 2638
2025
Q2 		$203 Hold
112
– – ﹤0.01% 2672
2025
Q1 		$228 Sell
112
-1
-0.9% -$4 ﹤0.01% 2660
2024
Q4 		$674 Hold
113
– – ﹤0.01% 1806
2024
Q3 		$1.1K Buy
+113
New +$1.52K ﹤0.01% 1687

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkside Financial Bank & Trust's BTAI Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 112 shares worth $158. The position accounts for ﹤0.01% of the portfolio, ranked #2675.

Parkside Financial Bank & Trust first reported a position in BTAI in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.1K in Q3 2024. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Parkside Financial Bank & Trust held 112 shares of BioXcel Therapeutics worth $158 as of Q2 2026.
  • Parkside Financial Bank & Trust left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2675 holding.
  • Parkside Financial Bank & Trust first reported a position in BioXcel Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Parkside Financial Bank & Trust's BioXcel Therapeutics position peaked at $1.1K in Q3 2024.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.